Neurocrine Biosciences Inc (NBIX) stock
NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 20/3012% below fair value
$167.40−2.00 (-1.18%)
Close on Nov 13, 2026Market cap $17.02BP/E 24.8Yield –
Neurocrine Biosciences EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Neurocrine Biosciences's EV/EBITDA was 21.8× on Nov 11, 2026, against 25.5× a year earlier. Over the last 5 years it ranged from 16.9× to 156.9×, with a median of 28.1×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 21.8× | −1.9 |
| 2025 | Dec 31, 2025 | 23.7× | +1.9 |
| 2024 | Dec 31, 2024 | 21.7× | −36.3 |
| 2023 | Dec 29, 2023 | 58.1× | −39.6 |
| 2022 | Dec 30, 2022 | 97.7× | +63.0 |
| 2021 | Dec 31, 2021 | 34.7× | −22.5 |
| 2020 | Dec 31, 2020 | 57.2× | −120.5 |
| 2019 | Dec 31, 2019 | 177.7× | −29.3 |
| 2018 | Dec 31, 2018 | 207.0× | −75.1 |
| 2013 | Apr 30, 2013 | 282.1× | +271.2 |
| 2012 | Oct 31, 2012 | 10.9× | +0.4 |
| 2011 | Dec 30, 2011 | 10.5× | – |
See a number that looks wrong?